Ming Bioventures

Founded 2018


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 5
Average round size
The average size of a deal this fund participated in
Portfolio companies 9
Rounds per year 1.67
Lead investments 1
Exits 1
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Life Science
  • Medical

Ming Bioventures appeared to be the VC, which was created in 2018. The main office of represented VC is situated in the Suzhou. The fund was located in Asia if to be more exact in China.

The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this Ming Bioventures performs on 4 percentage points more the average number of lead investments. The important activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Ming Bioventures, startups are often financed by Sequoia Capital China, SBCVC. The meaningful sponsors for the fund in investment in the same round are Yingqi Investment, Xiamen Changrong Investment Management, Tencent Holdings.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Medical Device, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight SyMap Medical, Viva Biotech.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Abogen Biosciences

Life Science
$92M08 Apr 2021 Gusu District, Jiangsu, China

Life Science
$20M22 Mar 2021 Lower Gwynedd Township, Pennsylvania, United States


Medical Device
$23M15 May 2020 Gusu District, Jiangsu, China

SyMap Medical

Health Care
Medical Device
$10M12 Nov 2018 China, Jiangsu

EndoClot Plus

Health Care
Medical Device
26 Oct 2018 San Jose, California, United States
Tavotek Biotherapeutics Snares $20M in Series A

– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ming Bioventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: